


Advent France Biotechnology participe au tour de table de Série B de 74M$ (61,5M€) d’AgomAb Therapeutics

Advent France Biotechnology crée Gamut Therapeutics et finance son amorçage

Advent France Biotechnology appoints Geoffroy de Ribains as operating partner

Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology
